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Pegylation of Antimicrobial Peptides Maintains the Active Peptide
Conformation, Model Membrane Interactions, and Antimicrobial
Activity while Improving Lung Tissue Biocompatibility following
Airway Delivery
Christopher J. Morris,a* Konrad Beck,b Marc A. Fox,c David Ulaeto,c Graeme C. Clark,c and Mark Gumbletona
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdoma; School of Dentistry, Cardiff University, Cardiff, United Kingdomb; and
Biomedical Sciences, Defence Science and Technology Laboratory, Porton Down, Salisbury, United Kingdomc
Antimicrobial peptides (AMPs) have therapeutic potential, particularly for localized infections such as those of the lung. Here we
show that airway administration of a pegylated AMPminimizes lung tissue toxicity while nevertheless maintaining antimicro-
bial activity. CaLL, a potent synthetic AMP (KWKLFKKIFKRIVQRIKDFLR) comprising fragments of LL-37 and cecropin A pep-
tides, was N-terminally pegylated (PEG-CaLL). PEG-CaLL derivatives retained significant antimicrobial activity (50% inhibitory
concentrations [IC50s] 2- to 3-fold higher than those of CaLL) against bacterial lung pathogens even in the presence of lung lin-
ing fluid. Circular dichroism and fluorescence spectroscopy confirmed that conformational changes associated with the binding
of CaLL to model microbial membranes were not disrupted by pegylation. Pegylation of CaLL reduced AMP-elicited cell toxicity
as measured using in vitro lung epithelial primary cell cultures. Further, in a fully intact ex vivo isolated perfused rat lung
(IPRL) model, airway-administered PEG-CaLL did not result in disruption of the pulmonary epithelial barrier, whereas CaLL
caused an immediate loss of membrane integrity leading to pulmonary edema. All AMPs (CaLL, PEG-CaLL, LL-37, cecropin A)
delivered to the lung by airway administration showed limited (<3%) pulmonary absorption in the IPRL with extensive AMP
accumulation in lung tissue itself, a characteristic anticipated to be beneficial for the treatment of pulmonary infections. We con-
clude that pegylation may present a means of improving the lung biocompatibility of AMPs designed for the treatment of pul-
monary infections.
Antimicrobial peptides (AMPs) are short 15- to 40-mercationic peptides which are produced naturally by both eu-
karyotes and prokaryotes and which possess microbicidal activity
against a range of bacterial and virus species. AMPs have attracted
considerable interest as synthetic, molecularly tunable agents that
may potentially subvert a number of microbial-resistance mech-
anisms (21). However, their physical properties (i.e., cationic
charge, peptidic composition) present challenges in the creation
of biologically stable agents and in balancing antimicrobial effi-
cacy against host cell membrane toxicity.
In the treatment of respiratory tract infections, local inhaled
delivery of antimicrobial agents may be particularly appropriate,
and especially so for AMPs, whose stability may be poor when
administered by other mucosal routes or indeed following intra-
venous administration. Exogenous delivery of natural AMPs into
the lung has clinical precedence; e.g., colistin, a mixture of several
natural peptides (polymyxins), is nebulized for the management
of pulmonary infections in cystic fibrosis patients (31). Local lung
deliverymay also offer potential for greater antimicrobial concen-
trations in the lung epithelial lining fluid (ELF) to combat infec-
tionwhile concurrentlyminimizing systemic exposure. Neverthe-
less, concern over local AMP-induced pulmonary toxicities will be
heightened.
In the few in vivo experimental studies that have examined lung
antimicrobial efficacy of airway-administered AMPs (3, 6, 11, 23,
47), the effectiveness in clearing lung infection has been variable.
While such mixed success likely reflects multifactorial differences
in themodes of action of the various AMPs, themicrobial burden,
and the character of the lung infection model itself, another crit-
ical determinant about which little is known is the pulmonary
disposition of AMPs following local delivery.
We have previously reported (15) on the design of a novel
21-mer peptide (CaLL) composed of fragments from the human
cathelicidin peptide LL-37 and the silk moth peptide cecropin A.
The synthetic hybrid CaLL displayed potent antimicrobial activity
in vitro against the pulmonary pathogens Bacillus anthracis and
Burkholderia cepacia; however, this was accompanied by high he-
molytic activity. It is well documented that pegylation of proteins
and peptides can elicit steric hindrance to reduce interactionswith
cells and enzymes (43).When CaLL was conjugated with polyeth-
ylene glycol (PEG), a modest but nevertheless significant decrease
in hemolytic activity of CaLL was observed (15).
In this study, we tested the hypothesis that pegylation of an
inhaledAMPwouldminimize pulmonary cell and lung tissue tox-
icity while nevertheless still affordingmaintenance of effective an-
timicrobial activity. Using both primary cultures of lung epithelial
cells and an intact lung model, i.e., the isolated perfused rat lung
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(IPRL), we assessed the lung toxicity associated with LL-37 and
cecropin A and that associated with the synthetic AMPs CaLL and
CaLL N-terminally conjugated to low-molecular-weight PEG
chains (PEG-CaLL). Antimicrobial activity was assessed against
both Gram-negative and Gram-positive bacteria. The airway ad-
ministration of the AMPs into the IPRL also provided unique
information on the pulmonary residence and systemic absorption
of lung-administered AMPs. Further, using cell biological and
biophysical approaches, we explored the previously reported phe-
nomenon that pegylation of AMPs has beneficial effects on the
selectivity of interaction between prokaryotic and eukaryotic cell
membranes (20). Using both circular dichroism (CD) and fluo-
rescence spectroscopy, the biophysical interactions of the AMPs
with artificial lipid models of eukaryotic and prokaryotic mem-
branes were examined to explore the issues of AMP conformation
and membrane selectivity.
MATERIALS AND METHODS
Tissue culture plastics were fromCorning (HighWycombe, United King-
dom). 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC)
and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerol (POPG)
were purchased from Avanti Polar Lipids (Alabaster, AL) as dry powders.
All other reagents and general lab consumables were purchased from
Fisher (Loughborough, United Kingdom) or Sigma-Aldrich (Poole,
United Kingdom).
Bacterial strains, growth conditions, and media. Staphylococcus au-
reus 29213, Escherichia coli 25922, and Bacillus anthracisUM23-CL2 were
obtained from the culture collection at the Defence Science and Technol-
ogy Laboratory (DSTL) (Porton Down, Salisbury, United Kingdom). All
strains were handled under Advisory Committee on Dangerous Patho-
gens (ACDP) level II conditions and were maintained on lysogeny broth
(LB) or LB agar. All strains were cultured at 37°C.
Preparation of B. anthracis spores. B. anthracis UM23-CL2 was cul-
tured on new sporulation medium (3.0 g Difco tryptone, 6.0 g Oxoid
bacteriological peptone, 3.0 gOxoid yeast extract, 1.5 gOxoid Lab Lemco,
1ml 0.1%MnCl2 · 4H2O, and 25 gDifco Bacto agarmade up to 1 liter with
H2O) in Roux bottles at 37°C until the cultures containedmore than 95%
phase-bright spores, as measured by phase-contrast microscopy, typically
between 7 and 10 days. The spores were harvested by centrifugation at
10,000  g for 10 min and then washed 10 times with ice-cold distilled
water to remove any vegetative cells and cell debris. The spore preparation
was heated at 70°C for 1 h to kill any remaining vegetative cells, and then
the final spore concentration was determined by serial dilution. Spore
preparations were stored at20°C until they were required.
Animals. Male specific-pathogen-free Sprague-Dawley rats (250 to
350 g; Harlan, United Kingdom) were used throughout and housed in
rooms maintained at 20 to 25°C and 40 to 70% relative humidity. The
animals had free access to food and water during acclimatization for2
days prior to experimentation. All animal experiments and the protocols
described below adhered to the Animal (Scientific Procedures) Act 1986
(United Kingdom).
Peptide synthesis, characterization, and quantitation. The peptides
listed in Table 1 were synthesized by Alta Biosciences (Birmingham,
United Kingdom) at a purity of90%. Subscript numbers in PEG2-CaLL
and PEG3-CaLL denote the number of 22-atom PEG units attached se-
quentially to the N terminus of CaLL to form a linear PEG chain.
HPLC. Peptide purity was assessed by reversed-phase high-perfor-
mance liquid chromatography (HPLC) using a Luna C18 column (4.6 by
150mm; Phenomenex, United Kingdom) attached to a Thermo Finnigan
HPLC system. HPLC was performed using a binary gradient: 0 to 5 min,
95%A; 5 to 35min, linear gradient from 95 to 0%A; 35 to 45min, hold at
0% A; 45 to 50 min, linear gradient from 0 to 95% A, where mobile phase
A was 0.1% (vol/vol) trifluoroacetic acid (TFA) in H2O and B was 0.1%
(vol/vol) TFA in acetonitrile (MeCN). Peptide elution was monitored
simultaneously at 220 and 254 nm.Cecropin, CaLL, and PEG2-CaLL sam-
ples were also monitored using fluorescence detection (ex, 280 nm; em,
348 nm).
LL-37 ELISA. LL-37 was detected in isolated perfused rat lung (IPRL)
perfusate samples, bronchoalveolar lavage fluid (BALF), and tissue ho-
mogenates using a commercially available enzyme-linked immunosor-
bent assay (ELISA) kit (Hycult Biotech, Frontstraat, Netherlands). Kits
were used according to the manufacturer’s instructions.
Mass spectrometry. Peptidemolecular masses were measured byma-
trix-assisted laser desorption ionization–time of flight (MALDI-TOF)
mass spectrometry using -cyano-4-hydroxycinnamic acid as a matrix.
Spectra were recorded on aWatersMicroMassMX spectrometer (Waters,
MA) in reflectron mode.
In vitro assessment of antimicrobial activity. The antimicrobial ac-
tivities of AMPs were determined as a 50% inhibitory concentration
(IC50), i.e., the lowest peptide concentrations at which bacterial growth
was inhibited by 50%, using the modified microtiter broth dilution
method (41). For these assays, spores or bacterial cells cultured to early
exponential phase were used at 105 to 107 (typically 106) CFU/ml and
tested against AMPconcentration ranges of 62.5g/liter to 128mg/liter in
2-fold dilution steps. Microtiter plates were prepared immediately prior
to use, with peptide concentrations, arranged in triplicate, suspended in
100 l 0.02% acetic acid and 0.4% bovine serum albumin (BSA/AA buf-
fer; Sigma-Aldrich, United Kingdom). A suspension containing 100l of
diluted bacteria was added to each well of a 96-well microtiter plate, ex-
cept for the negative controls, where just broth was added. Plates were
incubated at 37°C for 16 h. Bacterial growthwas determined bymeasuring
the absorbance at 620 nm with a Bio-Tek EL800 microplate reader (Bio-
Tek Industries, Bedfordshire, United Kingdom). IC50s were determined
for eachAMPas the concentrationnecessary to inhibit bacterial growth by
50% or more compared to the growth observed in control wells.
In vitro cell viability assay in primary rat lung alveolar epithelial
cells. The isolation and primary culture of type II rat alveolar epithelial
(ATII) cells was undertaken according to procedures reported previously
(2). Over 6 to 8 days of culture, ATII cells have been shown to adopt a
phenotypemore characteristic of alveolar epithelial type-I-like (ATI-like)
cells (9) whereas day 2 cultures retain the features of the ATII cell pheno-
type. AMPs prepared as 2-mg/ml stock solutions in sterile phosphate-
buffered saline (PBS) were serially diluted in full culture medium (con-
TABLE 1 Sequence data of peptides used in this study
Peptide Sequencea
Molecular mass (Da)
Theoretical Measured
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 4,493.3 4,493.0
Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK 4,004.8 4,006.4
CaLL KWKLFKKIFKRIVQRIKDFLR 2,791.5 2,791.6
PEG2-CaLL (PEG)2-KWKLFKKIFKRIVQRIKDFLR 3,462.3 3,463.0
PEG3-CaLL (PEG)3-KWKLFKKIFKRIVQRIKDFLR 3,797.7 3,798.9
a Underlined amino acids identify those sequences combined to make CaLL.
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taining the necessary volume of PBS vehicle as a control). Primary
cultures were incubated with AMP solutions at 37°C for 8 h in a cell
culture incubator, and cell viability was determined using the MTT sub-
strate as described previously (38).
Assessment of pulmonary barrier toxicity and AMP pulmonary ab-
sorption in an IPRL model. An IPRL preparation employing a forced
intratracheal solution instillation technique was used as previously de-
scribed (8, 27, 33). Briefly, a rat lung was surgically removed and housed
horizontally in a humidified artificial glass thoraxmaintained at 37°C. The
lung was perfused (15 ml/min) through the pulmonary artery with per-
fusate comprisingKrebs-Henseleit buffer supplementedwith 4% (wt/vol)
bovine serum albumin (BSA). The lungs were ventilated under positive
pressure with atmospheric air at a tidal volume of 2.5 ml, 20 cycles per
min.
AMPdosing solutions (0.1ml)were prepared containing 100g of the
respective AMP dissolved in 20 mM PBS, pH 7.4. Dosing solutions also
contained a nominal dose of0.2 Ci [14C] mannitol and 200 g 4-kDa
fluorescein isothiocyanate (FITC) dextran (FD4000) serving as transport
probes tomonitor pulmonarymembrane integrity.Dosing solutionswere
administered into the airways of the IPRL as a coarse spray through a
single actuation of the pressurized metered dose inhaler, delivering 5.5
cm3 propellant vapor. Serial aliquots were sampled from the recirculating
perfusate at predetermined times and centrifuged (13,000  g, 10 min,
4°C) to remove trace blood cells, and the supernatant was stored at20°C
until assay. To quantify AMP content, BALF and perfusate samples (0.5
ml) were treatedwith 1mlMeCN and incubated for 5min on ice and then
centrifuged at 12,000  g to sediment the protein pellet. Supernatants
were transferred to clean tubes and stored at 20°C. Lung tissue was
homogenized and extracted into 5 ml of 60% MeCN plus 1% trifluoro-
acetic acid and mixed end over end at 4°C. This was followed by centrif-
ugation at 12,000  g to sediment insoluble material, and then the ho-
mogenate was syringe filtered (0.2-m-pore-size filter) into a 10-ml
round-bottom flask before all solvent was removed under reduced pres-
sure. Extracted CaLL, PEG-CaLL, and cecropin were redissolved in 2 ml
H2O plus 0.1% TFA prior to HPLC analysis. LL-37 was resuspended in
PBS prior to quantification by ELISA. Quantitation of the permeability
probe [14C]mannitol was by liquid scintillation counting using a Tricarb
2900TR (Perkin Elmer, Shelton,CT). The permeability probe FD4000was
quantified by microplate fluorescence spectroscopy (ex, 485 nm; em,
520 nm; FLUOstar; BMG, Aylesbury, United Kingdom) using calibration
curves constructed in perfusate solution. Cumulative mass transfer of
analyte was determined by multiplying the sample concentration by the
total volume of perfusate, correcting for mass removed during sampling,
as described previously (27).
Proteolytic stability of AMPs in BALF.BALFwas harvested from rats
that had been euthanized by a pentobarbital overdose and cervical dislo-
cation. The trachea was cannulated with a 23G intravenous cannula, and
then the lungs were removed from the thoracic cavity en bloc. Lungs were
lavaged by the introduction under gravity of three 5-ml aliquots of normal
saline. BALF harvested from three animals was pooled and transferred to
sterile 12-well plates that had been blocked overnight with 0.5% (wt/vol)
BSA in PBS to prevent nonspecific adsorption. AMPs were incubated in
BALF or normal saline (control) at a concentration of 0.4mg/ml for up to
12 h. Samples (0.3 ml) were taken at predetermined time intervals and
immediately centrifuged at 12,000  g for 5 min to pellet luminal cells.
BALF supernatants weremixed with two volumes ofMeCN to precipitate
proteins and then applied to an ultrafiltration plate with a molecular
weight cutoff of 10,000 (Millipore, Watford, United Kingdom) and cen-
trifuged at 4,235 g at 4°C for 90 min (Rotanta 460R; Hettich Lab Tech-
nology, Tuttlingen, Germany). Ultrafiltrate samples were stored at20°C
before analysis by HPLC. To ensure correct interpretation of our HPLC
data, the concentration of each BALF-incubated sample was normalized
to the recovery of peptide from the saline-only control at each time point,
thus accounting for nonspecific loss through peptide adsorption to the
plasticware and filters. The recovery of each peptide was calculated from
the time zero sample and found to be 90% for all analytes. The intra-
assay analytical precision was determined to be 5% relative standard
deviation (RSD), as determined from separate injections of 100-g/ml
standard peptide solutions.
Antimicrobial activity of AMPs in the presence of BALF. The anti-
microbial efficacy of AMPs against B. anthracis spores was determined in
the presence of BALF at an initial AMP concentration of 100 g/ml (22
MLL-37, 35MCaLL, and 30MPEG2-CaLL). Briefly, 180l of BALF
wasmixedwith 40l of a 10 concentrate of CaLL, PEG2-CaLL, or LL-37
(1 mg/ml in BSA/AA buffer) and then mixed with 180 l of B. anthracis
spore suspension (106 spores/ml). Samples were removed at 0, 0.5, 1, 2,
3, and 4 h and serially diluted in PBS. Viable bacteria were enumerated on
agar plates. To control for possible effects of BALF on bacterial growth,
additional samples were prepared where 40 l of the AMP solution was
replaced with BSA/AA buffer.
CD spectroscopy. Spectra were recorded on an Aviv 215 CD spectro-
photometer (Aviv Biomedical Inc., Lakewood, NJ; 1-nm bandwidth,
0.2-nm steps, 3 to 5 s per point accumulation) equipped with a thermo-
statted cell holder. Samples were prepared in 100 mM NaF–20 mM
KH2PO4-NaOH, pH 7.2 (CD buffer). NaF was used to avoid the chloride
absorbance of NaCl at a  of195 nm. Spectra were recorded in a 0.1-cm
quartz cell at peptide concentrations of 0.1 to 0.2mg/ml determined from
the optical density at 280 nm (OD280) assuming absorption coefficients
calculated from the amino acid composition (30) or, in the case of LL-37,
the peptide bond absorbance (36). Buffer baselines were subtracted, and
data were smoothed and normalized to mean residue ellipticities with the
equation [	]MRW 
 	obs  MRW/(l  c), where 	obs is the observed
ellipticity (mdeg),MRWthemean residueweight, l the path length (mm),
and c the concentration (mg/ml). The instrument was calibrated with
camphorsulfonic acid (10). -Helical content fH was estimated from
[]222 as fH
 ([]222[]c)/([]h[]c) with []c
 2,20053 T
and []h
 (250T44,000)/(13/n), whereT is the temperature (°C)
and n the number of residues (25). Induction of -helix formation by
2,2,2-trifluoroethanol (TFE) was monitored at 222 nm, and data were
fitted assuming a one-site binding mechanism fH 
 fh
max  c/(KD  c),
where fh
max and KD are the maximum helix fraction achievable and ap-
parent dissociation constant, respectively.
Small unilamellar vesicles (SUV). Thin lipid films were produced by
rotary evaporation of lipid solutions (10 mg/ml in chloroform) and fur-
ther drying overnight under vacuum. Films were hydrated at a lipid con-
centration of 10mg/ml in eitherCDbuffer or PBS. Lipid suspensionswere
subjected to 10 freeze-thaw cycles (2 min in liquid N2, 5 min in a 37°C
water bath, 2 min vortex mixing) and left overnight at room temperature
(RT). Vesicle suspensions were extruded 10 times at RT through two
stacked 100-nm or 50-nm Nuclepore membranes (Whatman, United
Kingdom) for fluorescence and CD experiments, respectively. Vesicles
were stored at RT and used within 24 h.
Fluorescence spectroscopy. Fluorescence spectra were recorded on
an Aminco-Bowman Series 2 luminescence spectrometer (SLM-Aminco
Spectroscopic Instruments, Rochester, NY). A 200-l portion of CaLL or
PEG2-CaLL (4 M) was mixed 1:1 (vol/vol) with lipid vesicle suspension
to give a final lipid concentration between 0 and 50 M. Tryptophan was
excited at 280 nm and the emission spectrum scanned between 300 and
450 nm at 1-nm increments over 75 s. Emission curves were fitted using a
Gaussian nonlinear regression analysis (GraphPad Prism v4.0) to deter-
mine individual max values for each scan.
RESULTS
In vitro AMP activity. To determine whether the attachment of
small PEG chains to the N terminus of CaLL effected a change in
antimicrobial potency, IC50s were determined against a select
range of bacteria. Table 2 shows the IC50s for CaLL and two pegy-
lated derivatives against Gram-positive B. anthracis (both vegeta-
tive and spore forms) and against the Gram-positive S. aureus and
the Gram-negative E. coli. Compared to the parental LL-37 pep-
Morris et al.
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tide, CaLL was more potent against germinating B. anthracis
spores by almost 5-fold and at least 11-fold more potent against
the vegetative form.
The pegylated CaLL derivatives retained significant antimicro-
bial activity, with the IC50s remaining within an order of magni-
tude of that of CaLL. The PEG2 conjugate retained the greater
potency compared to the PEG3 conjugate, with the former dis-
playing only a 2-fold- to 3-fold-higher IC50 compared to CaLL
toward B. anthracis and E. coli.
Lung epithelial toxicity of AMPs. The potential for AMPs to
induce membrane damage to lung epithelial cells over an 8-h pe-
riod was investigated using the MTT assay with primary cultures
of rat lung alveolar epithelial (AE) cells. Both the ATII and the
ATI-like cultures showed decreases in cell viability with increases
in AMP concentration. At the highest AMP concentration tested
(90M) the cell viability of the ATII cells (Fig. 1A)was reduced by
more than 60% by CaLL and by 40% and 30% following exposure
to PEG2-CaLL and PEG3-CaLL, respectively. The loss of cell via-
bility wasmore profound in the attenuated ATI-like cells (Fig. 1B)
with a70% loss of viability associated with CaLL and the PEG2-
and PEG3-CaLL derivatives at 90 M. The response of the ATII
and ATI-like cells to cecropin A and LL-37 peptides was less consis-
tent (Fig. 1C and D). Even at the highest concentration tested (90
M) the LL-37 peptide did not affect the turnover of theMTTdye in
theATII cells (Fig. 1C) although it did elicit an approximate 60% loss
inMTT turnover in theATI-like cells (Fig. 1D). In contrast, cecropin
A (90 M) appeared to have no adverse effect in ATI-like cells (Fig.
1D) but reduced the viability of ATII cells by 60% (Fig. 1C). The
effects of AMPs were comparable when cells were incubated with
AMPs inmediumwithout serum (data not shown).
We next assessed in the IPRL model the integrity of the intact
pulmonary barrier over a 90-min period following administration
of the AMPs into the airways. This was achieved by coinstillation
(simultaneously with the AMP) of the hydrophilic paracellular
permeability probe [14C]mannitol or FD4000. The pulmonary ab-
sorption half-life (t1/2) for mannitol administered alone (i.e.,
without AMP) was 19 min (Table 3). However, upon coinstilla-
tion with 30 nmol CaLL, the mannitol absorption t1/2 shortened
considerably (P 0.05), to 3min, indicating that the permeability
of the IPRL epithelium tomannitol had greatly increased. Further,
at the 30-nmol dose of CaLL there was significant visual evidence
of pulmonary edema developing soon after dosing. In contrast,
instillation of an equivalent molar dose of PEG2-CaLL (33 nmol)
failed to cause any visible evidence of edema and no barrier per-
turbation, as evidenced by themannitol absorption t1/2 remaining
similar (P 0.05) to the control value. Reducing the dose of CaLL
TABLE 2 Antibacterial activity of AMPs
Bacterial type Strain
IC50 (M)
a
CaLL PEG2-CaLL PEG3-CaLL LL-37
Gram positive B. anthracis
spores
2.8 4.5 8.2 13.9
B. anthracis
vegetative
5.6 9.0 16.5 65
S. aureus 2.8 18.1 16.5 ND
Gram negative E. coli 0.7 2.3 8.2 ND
a IC50 values (n
 3). ND
 not determined.
FIG 1 In vitro biocompatibility of AMPs. ATII primary cultures of rat AE cells were incubated for 8 h with increasing concentrations of CaLL or pegylated CaLL
derivatives (A) or cecropin A and LL-3 (C). ATI-like primary cultures of rat AE cells were incubated with increasing concentrations of CaLL or pegylated CaLL
(B) or cecropinA and LL-37 (D). Data shown aremeans standard errors of themeans (SEM) (n 6 from three different primary cultures). AMPswere applied
in full culture medium including 10% serum.
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by 10-fold (3 nmol CaLL) also prevented any grossmorphological
evidence of pulmonary barrier alteration or quantitative changes
in mannitol absorption (Table 3). This observation indicates that
pegylation of CaLL had a profound beneficial impact to reduce
CaLL toxicity in the IPRL model. With respect to the parental
peptides, no change (P 0.05) in the pulmonary absorption t1/2 of
mannitol was evident upon coinstillation with LL-37 (12 nmol).
However, a surprising and as-yet-unexplained lengthening (P 
0.05) in mannitol absorption t1/2 was observed when coadminis-
tered with cecropin A (deposited dose, 21 nmol), which was in-
dicative of a retardation in the mannitol absorption process or a
reduced availability of mannitol for absorption. We also studied
the effect of the AMPs upon the IPRL permeability to coinstilled
FD4000, a larger 4-kDa hydrophilic permeability probe. Here, the
onlyAMPcoinstillation treatment to alter FD4000permeability in
the IPRL model was again high-dose (30-nmol) CaLL, which sig-
nificantly (P  0.05) shortened the absorption half-life (t1/2) of
FD4000, indicating acute barrier perturbation (data not shown).
Pulmonary absorptionofAMPs in the IPRLmodel.The IPRL
model was also used to examine the pulmonary disposition of
each of the AMPs. Table 3 also shows the lung-deposited dose for
each of the peptides administered into the IPRL and the extent of
AMP dose absorption across the lung epithelial barrier into the
perfusate (i.e., vascular compartment of the IPRL) by 90min. The
concentrations of cecropin A, CaLL, and PEG2-CaLL in pulmo-
nary perfusate samples at the end of each 90-min IPRL experiment
were below the lower limit of detection (LLD) (fluorescence
HPLC assay LLD of 50 ng/ml). This indicates a low extent of
absorption from the airways. Specifically, based on the LLD and
an average final IPRL perfusate volume of approximately 50 ml,
the theoretical maximal possible extent of pulmonary absorption
for cecropin A, CaLL, and PEG2-CaLL could not be greater than
3% of the AMP dose, and in all probability it was considerably
lower than this. This estimation was reinforced by the absorption
data for LL-37, which was quantified using an ELISA (limit of
quantification, 0.1 ng/ml). For LL-37 we determined only
0.5%  0.1% of the lung-deposited LL-37 dose to be absorbed
over the 90-min IPRL experiment. The mass balance recovery for
theAMPs from the combined perfusate, lung tissue, and lung ELF,
the latter obtained with significant dilution by bronchoalveolar
lavage, was consistently high, within the range of 83 to 94% of the
deposited AMP dose. However, a mass balance assessment for the
PEG2-CaLL peptide conjugate was not possible, as it was unde-
tectable in BALF and lung tissue although confirmed to be fully
intact in the IPRL dosing solution.
Proteolytic stability and bactericidal kinetics of AMPs in the
presence of BALF. To investigate further the disposition of AMPs
in the airway luminal environment, each of the AMPs was incu-
bated in fresh rat BALF and the kinetics of AMP degradation was
determined (Fig. 2). LL-37 showed the greatest proteolytic stabil-
ity, evidenced by 80% intact peptide remaining at 12 h. Some
50% of cecropin A was recovered intact after 12 h of in vitro incu-
bation in BALF. The stability of CaLL was intermediate between
the two parental peptides, while the stability of the PEG2-CaLL
derivative was considerably lower (P 0.05) than all other AMPs
tested; i.e.,50% of PEG2-CaLL peptide conjugate was degraded
within 1 h. This degradation involved breakdown of the peptide
component, as quantitative analysis could not detect the presence
of free intact CaLL in the in vitroBALFmedium (data not shown).
Of note, in control studies with incubations of the AMPs at 37°C
in sterile saline, all of the peptides (including the pegylated deriv-
atives) displayed minimal degradation, with each AMP showing
80% stability over the 12 h of the incubation period (data not
shown).
Acknowledging the potential for lung components to attenuate
the potency of AMPs delivered into the pulmonary tract, the bacteri-
cidal kinetics of AMPs were determined in the presence of rat lung
BALF. Figure 3 shows the AMP-mediated killing of germinating B.
anthracis spores in the standard bacterial culture medium (Fig. 3A)
and in culturemediumcontaining 50% (vol/vol) rat lungBALF (Fig.
3B). In the absence of BALF, CaLL killed approximately 99% of B.
anthracis spores within 1 h of spore germination commencement
(represented as time zero in Fig. 3); the rate of PEG2-CaLL-mediated
kill was similar, i.e.,95% bacterial kill within 1 h (Fig. 3). The rates
of B. anthracis kill by all AMPs tested were not significantly slowed
(P  0.05) by the presence of rat BALF. Under both experimental
conditions CaLL and PEG2-CaLL displayed greater activity against
germinating spores than LL-37.
Solution conformation ofAMPs.The solution conformations
of peptides cecropin A, LL-37, and CaLL with and without PEG
chains attached were evaluated by CD spectroscopy. Cecropin A
shows a minimum at 200 nm and a shoulder around 220 nm
indicative of a mainly unordered secondary structure (Fig. 4A),
FIG 2 In vitroAMP stability in fresh rat BALF. AMPs (0.3 mg/ml) were added
to BALF and incubated at 37°C for up to 12 h. Samples were removed and the
amount of peptide present quantified by HPLC. Data shown are mean 
standard deviation (SD) (n 4). Only negative SD bars are shown for clarity.
TABLE 3 Permeability of pulmonary epithelium to mannitol and
pulmonary absorption of AMPs in the IPRL modela
Treatment
AMP deposited
dose (nmol)
Extent of AMP
absorptionb
Mannitol
absorption t1/2 (min)
c
Control 18.9 8.4
CaLL 30 0.7 3 2.6 1.3†
CaLL 3 0.4 18.3 1.1
PEG2-CaLL 33 5.1 3 16.1 5.9
LL-37 12 0.2 0.5 0.1 17.8 1.0
Cecropin A 21 0.2 3 31.6 1.2†
a Data shown are mean standard deviation (SD) (n 3).
b Extent of AMP absorption was determined at 90 min from the IPRL perfusate
concentration and the lung-deposited dose.
c Mannitol absorption t1/2 was determined by nonlinear regression of the cumulative
transport curves. †, P 0.05 compared to control by one-way analysis of variance
(ANOVA) and Dunnett’s post hoc test.
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which is in agreement with former studies on porcine cecropin P1
(37). The LL-37 spectrum, with minima at 222 and 208 nm and a
maximum at 192 nm, is characteristic for an -helical conforma-
tion at the given conditions, which agrees with published data
(22). The CaLL spectrum, with extrema at 192 and 205 nm, qual-
itatively represents an additive effect of the conformations of its
parent peptides, with a 2:1 contribution of cecropin A to LL-37,
suggesting that the two parts behave structurally independently.
PEG2-CaLL spectra exhibit the same characteristics as the unpe-
gylated peptide, though the CD amplitude is slightly increased,
which might indicate that the PEG chains preferentially stabilize
the ordered conformations of CaLL.
To estimate the possible structure formation in an environ-
ment with reduced water activity mimicking the hydrophobic
core of membranes (for a review, see reference 7), CD spectra of
CaLL (Fig. 4B) andPEG2-CaLL (Fig. 4C)were recorded at increas-
ing TFE concentrations. Even very low TFE concentrations had a
substantial effect, resulting in an increase of theCDamplitudes. At
higher concentrations, a clear minimum at 222 nm appeared re-
sulting in spectra similar to LL-37 in benign solvent. Fitting [	]222
as a function of TFE concentration assuming a one-binding-site
model, and relating the values to the degree of -helix content,
results in maximal helicities of 42 and 56% for CaLL and PEG2-
CaLLwith apparent dissociation equilibrium constants of 800 and
320 mM1 TFE, respectively (insets in Fig. 4B and C).
FIG 3 Bactericidal kinetics of AMPs. Kill kinetics of AMPs against germinat-
ing B. anthracis are shown. A 100-g/ml concentration of LL-37, CaLL, or
PEG2-CaLL was incubated with spores in the absence (A) or presence (B) of
50% (vol/vol) rat lung BALF. Data shown are means standard errors of the
means (SEM) (n 6). Error bars are within the area of the symbols.
FIG 4 CD spectra of AMPs in buffer. (A) CD spectra were recorded for cecropin
A (dotted line), LL-37 (dashed-dotted line), CaLL (solid line), and PEG2-CaLL
(dashed line) in CD buffer at 37°C. CaLL (B) and PEG2-CaLL (C) spectra were
recorded in thepresenceofTFE.Spectra showncorrespond toTFEconcentrations
of (fromtop tobottomat 220nm)0, 1, 2, 5, 10, and50%. Insets show the apparent
-helical content as calculated according to reference 25. Data were fitted to a
one-site binding model resulting in fH
max
 0.42 (CaLL) and 0.56 (PEG2-CaLL)
with apparent dissociation constants of 800 and 320 nM, respectively.
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AMPconformational changesupon lipidmembrane interac-
tion.Given the substantial effect observed for TFE on the confor-
mation of CaLL and PEG2-CaLL, we examined whether a similar
helical change could be induced by interaction with SUVs. All CD
experiments were conducted with 50-nm-diameter vesicles in or-
der to reduce light-scattering effects.Whereas no obvious changes
of the CD spectrum were seen when POPC (i.e., zwitterionic)
vesicles were mixed with cecropin A (Fig. 5A), LL-37 showed a
large increase in the CD amplitude (Fig. 5B), and the signal ob-
served for the hybrid peptides CaLL (Fig. 5C) and PEG2-CaLL
(Fig. 5D) indicated a transition from a mostly unordered state to
one containing a substantial degree of -helix, e.g., an increase by
a factor of 2.5 in the cases of CaLL and PEG2-CaLL (Table 4).
POPG (i.e., anionic) vesicles showed even larger effects, with an
3-fold increase of helical content for cecropin A, CaLL, and
PEG2-CaLL. Indeed, the -helical contents of CaLL and PEG2-
CaLL of 41 and 54% in the presence of POPG SUVs are in close
agreement with the values of 42 and 56%, respectively, extrapo-
lated from exposure of the peptides to TFE (Fig. 4B and C).
Fluorescence spectroscopy investigation of AMP lipidmem-
brane binding. Fluorescence spectroscopy was used to further
explore the lipid membrane-binding interactions of CaLL and
PEG2-CaLL with experiments conducted at peptide concentra-
tions approximating their IC50s (Table 1). Broadly, in these exper-
iments membrane binding of the peptide was indicated by a shift
(max) in emission maximum to shorter wavelengths while an
increase in fluorescence intensity (Fl) inferred greater sequestra-
tion of the tryptophan indole group into an environment of lower
polarity (i.e., the lipid membrane). Mixing CaLL with increasing
concentrations of POPG SUVs caused increases inmax andFI
(Fig. 6A and C) that were greater than the respective increases
observed when CaLL was mixed with POPC vesicles (Fig. 6A and
C). This is consistent with the CD data for CaLL. In contrast,
PEG2-CaLL showed a more marked preferential interaction with
POPG SUVs. For example, a 6-fold-greater max (Fig. 6B) and a
1.7-fold-greaterFI (Fig. 6D) were observed in the presence of 50
M POPG vesicles than in the interactions measured with an
equivalent 50Mconcentration of POPCvesicles (Fig. 6B andD).
Studies with the tryptophan-containing parental peptide cecropin
A also showed selectivity in lipid-membrane interactions toward
the POPG vesicles, although the magnitude of the difference be-
tween the anionic and zwitterionic membranes was not as great as
those recorded for PEG2-CaLL (data not shown).
FIG 5 CD spectra of AMPs in the presence of SUVs. Spectra were recorded for
cecropin A (A), LL-37 (B), CaLL (C), and PEG2-CaLL (D) at 37°C (solid lines)
and in the same buffer in the presence of POPC (dashed line) or POPG (dotted
line) SUVs (lipid concentration: 1 mg/ml).
TABLE 4 AMP -helical content in the absence and presence of POPC
and POPG SUVs
Peptide Lipid  helix (%)a
Cecropin A None 10
POPC 12
POPG 31
LL-37 None 36
POPC 50
POPG 58
CaLL None 13
POPC 33
POPG 41
PEG2-CaLL None 19
POPC 45
POPG 54
a Helix content derived from [	]222 at 37°C according to reference 24.
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DISCUSSION
We previously reported upon the design (15) and antimicrobial
activity (13) of CaLL, a synthetic AMP derived from selected se-
quence regions of the cecropin A and LL-37 peptides.While CaLL
possesses significantly greater antimicrobial effectiveness com-
pared to its parental AMPs, it also exhibits significant toxicity as
determined by increased CaLL-induced hemolysis. Recognizing
that improved outcomes can be gained by delivery of inhaled
AMPs for the local treatment of pulmonary infections, we exam-
ined if pegylation of CaLL provided an advantage in terms ofmin-
imizing pulmonary lung tissue toxicity and in the pulmonary
pharmacokinetics of the AMPwhile nevertheless maintaining an-
timicrobial activity. Further, using spectroscopic techniques we
explored the hypothesis that pegylation of CaLL would lead to
selectivity of interaction with prokaryotic cell membranes. En-
hanced AMP potency through improved selectivity for bacterial
membranes might therefore reduce the requisite dose of costly
peptide drugs while concurrently improving biocompatibility.
Extending previous studies of the antimicrobial activity of
CaLL (13), here we investigated activity against the pulmonary
pathogen B. anthracis (in spore and vegetative forms) and also
against laboratory strains of E. coli and S. aureus, both of which are
potential pulmonary pathogens. We found CaLL to be signifi-
cantlymore potent against all bacterial organisms tested thanwere
its parent peptides; the IC50s of CaLL observed againstB. anthracis
were among the lowest reported for AMPs tested against the
Sterne strain of B. anthracis (12, 24). We also noted that CaLL
displayed slightly higher potency against the germinating spore
form of B. anthracis, substantiating further investigations into the
use of CaLL in the prevention of pulmonary infection following
exposure to B. anthracis spores. Previous reports of AMP pegyla-
tion, employed for the purposes of increasing peptide solubility or
improving proteolytic stability, have documented decreases in an-
timicrobial activities of between 4- and 30-fold against non-spore-
forming bacteria (16, 18, 19, 46).We foundN-terminal pegylation
of CaLL only slightly diminished its antimicrobial activity, with
the PEG2 conjugate of CaLL retaining greater antimicrobial activ-
ity than the larger PEG3 conjugate. The additional 22-atom PEG
unit present in the latter may impart a conformation whereby the
PEG chain interferes with insertion of the modified CaLL into
bacterial membranes. The diminished activity of the PEG3 conju-
gate led subsequent experiments to focus on the biological and
mechanistic aspects of PEG2-CaLL.
Unfolded AMPs interact with membranes principally via elec-
trostatic and/or hydrophobic interactions with the lipid bilayer
surface. Subsequent insertion of peptide nonpolar side chains into
the interfacial membrane region is believed to accompany the
structural transition of the AMP to an -helical conformation
which disrupts the cell membrane and causes microbial death.
This conformational transition can be mimicked by exposing the
peptide to fluorinated solvents or artificial lipid membranes (7,
35). Using both CD and fluorescence spectroscopy, we examined
the induction of -helicity in the AMPs and their selectivity of
membrane interactions using lipidmodels of anionic (POPG) and
zwitterionic (POPC) model membranes.
In the in silico modeling and design of CaLL the aim was to
retain the critical ability of CaLL to form an -helical conforma-
tion (15). Our CD data confirmed this and that this content in-
creased in the presence of the fluorinated solvent TFE or lipid
SUVs. It is of note that a differential responsiveness toward lipid
vesicles was apparent between the parenteral cecropin A and
CaLL. Specifically, while the -helical content of the former was
not augmented by exposure to POPC vesicles, that of CaLL was
almost equally amplified by POPC or POPG SUVs. Our observa-
FIG 6 Fluorescence spectroscopy investigation of AMP lipid membrane interactions. Tryptophan fluorescence blue shifts (max) (A and B) and increases in
fluorescence emission intensity (FI) (C and D) were recorded in the presence of SUVs. Data for 2 MCaLL (A and C) and 2 M PEG2-CaLL (B and D) were
recorded upon titration of increasing concentrations of 100-nm-diameter SUVs comprising either POPG (empty symbols) or POPC (filled symbols).
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tions contrast with some reports showing pegylation of AMPs to
inhibit -helix formation, for example, that of Imura et al. (18),
who attached a 5-kDa PEG to the N terminus of magainin-2 pep-
tide.We found that pegylation of CaLL did not have a detrimental
impact upon -helical content in any of the environments we
studied. Indeed, the data indicated that the PEG chains may have
preferentially stabilized the ordered conformations of CaLL.
Fluorescence spectroscopy was exploited to extend our mech-
anistic understanding of CaLL activity and, in particular, the in-
teractions of CaLL and its pegylated derivative with anionic and
zwitterionic SUVs. Unlike the near-equivalent interactions of
CaLL with POPC and POPG SUVs, PEG2-CaLL showed marked
preferential interactions with the anionic POPG SUVs. CaLL is
composed of the first eight N-terminal residues from cecropin A,
a fragment enriched in positively charged amino acids. The re-
mainder of CaLL is comprised of 13 residues (residues 17 to 29)
from LL-37. Given the array of structural data available for ce-
cropin (37) and LL-37 (22, 40), an appropriate speculation for
CaLL interactions with a membrane would include initial mem-
brane anchoring of CaLL mediated through electrostatic interac-
tions of the cationic N-terminal residues from cecropin with the
propensity for CaLL to assume an -helical conformation being
attributable to the 13 residues from LL-37. Therefore, we could
propose that the presence of the PEG2 chain at the N terminus of
CaLL is sufficient to disrupt, to some extent, anchoring and sub-
sequent membrane insertion of the peptide with zwitterionic
membranes, while the PEG2 chain has less impact on the peptide
interactions with the more anion-rich POPG membranes.
With the aim of defining the pulmonary disposition and acute
biocompatibility of CaLL and pegylated CaLL derivatives in nor-
mal, uninfected lung models, we performed a series of experi-
ments that employed our unique combination of in vitro primary
rat AE cell cultures and the ex vivo IPRL model. These primary
cultures are a particularly valuable tool for the examination of
cellular toxicity; theATII cell, which covers only 5%of the alveolar
surface area, is accepted as the sole in vivo progenitor of the ATI
cell (42), which represents the remaining 95% of the surface area.
As might be expected from a highly cationic peptide (8 charge at
pH 7), CaLL reduced the viability of ATII and ATI-like cell cul-
tures over an 8-h incubation period, albeit most profoundly at
high concentrations on the order of 100 M. Notwithstanding
this, amodest reduction inmembrane damagewas afforded by the
attachment to CaLL of the PEG2 and PEG3 chains, an observation
supportive of the role of PEG to shield the detrimental interac-
tions of CaLL with epithelial cells. CaLL and pegylated CaLL re-
duced the cell viability of ATII as well as ATI cells, which indicates
that the role of the ATII cell in restoring alveolar epithelial con-
fluence after injury to ATI cells may be compromised. These in
vitromodels present simple single-cell phenotype monolayer cul-
tures and contrast markedly to the multicell phenotype and com-
plex architecture of the intact lung. OurMTT assays provide valu-
able information about the nature of epithelial toxicity that may
be observed at the alveolar epithelial surface when AMPs accumu-
late at the alveolar epithelial surface due to slow absorption into
the pulmonary vasculature.
The IPRLmodel afforded investigation of whole-lung biocom-
patibility of the AMPs through monitoring of the absorption of
coadministered hydrophilic probes, i.e., 182-Da mannitol and
4-kDa dextran. The improved lung biocompatibility arising from
pegylation of CaLL was clearly evidenced by PEG2-CaLL admin-
istration not leading to pulmonary barrier solute transport per-
turbation or the marked pulmonary edema seen with CaLL ad-
ministration. Although the IPRL experiment represented an acute
(90-min) exposure to AMPs, it nevertheless exposed the lung tis-
sue to high concentrations of AMPs predicted to have reached
close to 100-fold greater than the respective antibacterial IC50s
measured in earlier experiments. For example, based on an ac-
cepted ELF volume of 250 to 300l in a 250-g rat, a 30-nmol dose
of PEG2-CaLL would be predicted to give an in situ lung ELF
concentration, immediately after administration, of approxi-
mately 100 to 150 M peptide.
The administration of the AMPs into the airways of the IPRL
also provided the opportunity to collect information on the pul-
monary absorption and stability of these peptides. Over the 90-
min duration of the IPRL experiment the extent of absorption of
the 2.8- to 4.5-kDa AMPs into the pulmonary perfusate was very
low (3%). It is reasonable to predict from this that the AMPs
likely reside in the airway lumen for a prolonged period postad-
ministration, which would be beneficial for antimicrobial efficacy
within the lung lumen itself. Nevertheless, the low extent of ab-
sorption was unexpected, as the lung is recognized as one of the
more permeable epithelial barriers to the systemic absorption of
macromolecules, including the display of significant pulmonary
absorption of polypeptides and proteins (17). We (27) and others
(32) have previously reported on the relatively high bioavailability
ofmacromolecules administered via the lung, including for exam-
ple that of 4-kDa dextran, which displays an extent of pulmonary
absorption of approximately 30% over a 90-min IPRL experi-
ment, an observation which is consistent with 4-kDa dextran ab-
sorption in vivo (28). The AMPs utilized in this work are highly
cationic, with 22% to 43% of their respective peptide chains com-
prising basic amino acid residues. This is not unlike the cationic
peptides defined as cell-penetrating peptides (CPPs) (14), whose
systemic disposition is characterized by high tissue binding and
accumulation in well-perfused tissue beds, including that of the
lung (1, 34). Indeed, it is generally recognized that cationic char-
acter leads to a propensity for exogenously administered mole-
cules, even low-molecular-weight entities, to accumulate in lung
tissue (4). A variety of endogenous intraluminal molecules, in-
cluding lipids and proteins, have been associated with the pulmo-
nary sequestration and prolonged luminal retention of exoge-
nously administered polypeptides (26). A number of individual
ELF components, including surfactant proteins (45), apolipopro-
teinA1 (44), and albumin (39), have been shown to bind toAMPs.
Indeed, Bergsson and colleagues (5) recently reported that LL-37
undergoes electrostatic binding interactions with cell membrane
and matrix glycosaminoglycans (GAGs), a binding interaction
previously documented for a number of CPPs (48).
We studied the stability of the AMPs to rat lung BALF to de-
termine their potential as anti-infective agents for pulmonary de-
livery. While the PEG2-CaLL conjugate showed good stability in
saline, in contrast its stability in BALFwas relatively poor (t1/2,1
h) and not simply a reflection of removal of the PEG moiety but
instead involved breakdown of the peptide component.While it is
possible to conjecture that the lack of toxicity of PEG2-CaLL in the
IPRL was simply due to its degradation by what will be a more
enriched in vivoELF, this argument is notwholly sustainablewhen
one considers the almost instantaneous (within 1min postadmin-
istration) pulmonary edema induced by CaLL in the IPRL bio-
compatibility experiments and the avoidance of this hyperacute
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toxicitywhenPEG2-CaLLwas administered. The pegylation of the
CaLL peptide may decrease CaLL stability through disrupting the
capacity of CaLL to self-associate. For example, a growing body of
evidence supports the enzymatic stability of LL-37 through its
ability to undergo concentration-dependent self-association of
LL-37monomers (29). The reduced stability of PEG2-CaLL in the
presence of BALF may initially appear at variance with its bacte-
ricidal actions tested in this work in the presence of BALF. In
particular, against germinating B. anthracis spores we showed the
actions of pegylated CaLL to be at least as effective as CaLL itself
and indeed to be unaffected by the coincubation with BALF. Crit-
ically, the bactericidal actions in this assay reflect predominantly
the first hour following spore germination, where concentrations
of PEG2-CaLL will have remained at levels much greater than the
IC50. Repeated dosing of cationic AMPs displaying prolonged res-
idence in the lung lumen may cause deleterious effects on lung
integrity. The ability to control the rate of proteolytic cleavage of
such AMPs through pegylation, however, may offer an opportu-
nity to avoid potential harmful AMP accumulation in the lung at
the same time as providing efficacious antimicrobial cover.
In conclusion, we have demonstrated that attachment of a
short N-terminal PEG chain to CaLL offers improvements in the
acute lung biocompatibility of this AMP without interfering with
the critical membrane binding and peptide conformational
changes necessary for sustained antimicrobial potency. This study
provides evidence that pegylation may find utility in the develop-
ment of inhaled AMP therapeutics for pulmonary infection.
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